$460 Million is the total value of Broadfin Capital, LLC's 39 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was - .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
MRTX | New | MIRATI THERAPEUTICS INCcall | $20,600,000 | – | 200,000 | +100.0% | 4.48% | – |
AGN | New | ALLERGAN PLC | $19,222,000 | – | 114,804 | +100.0% | 4.18% | – |
BHVN | New | BIOHAVEN PHARMACTL HLDG CO Lcall | $17,516,000 | – | 400,000 | +100.0% | 3.81% | – |
RTRX | New | RETROPHIN INCput | $10,045,000 | – | 500,000 | +100.0% | 2.18% | – |
SIEN | New | SIENTRA INC | $8,624,000 | – | 1,400,000 | +100.0% | 1.88% | – |
SIBN | New | SI BONE INC | $6,364,000 | – | 312,898 | +100.0% | 1.38% | – |
AMRN | New | AMARIN CORP PLCspons adr new | $5,642,000 | – | 291,000 | +100.0% | 1.23% | – |
WMGI | New | WRIGHT MED GROUP N V | $3,769,000 | – | 126,400 | +100.0% | 0.82% | – |
RTRX | New | RETROPHIN INCcall | $3,014,000 | – | 150,000 | +100.0% | 0.66% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Broadfin Healthcare Master Fund Ltd #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
BIODELIVERY SCIENCES INTL IN | 27 | Q4 2019 | 4.8% |
HERON THERAPEUTICS INC | 24 | Q4 2019 | 9.0% |
LA JOLLA PHARMACEUTICAL CO | 24 | Q4 2019 | 7.7% |
RECRO PHARMA INC | 24 | Q4 2019 | 4.1% |
ANTARES PHARMA INC | 24 | Q3 2019 | 3.4% |
RETROPHIN INC | 23 | Q3 2019 | 7.0% |
ARATANA THERAPEUTICS INC | 22 | Q2 2019 | 8.1% |
MIRATI THERAPEUTICS INC | 22 | Q1 2019 | 7.9% |
CATALYST PHARM PARTNERS INC | 22 | Q3 2019 | 6.2% |
ANGIODYNAMICS INC | 21 | Q3 2018 | 6.6% |
View Broadfin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
Eiger BioPharmaceuticals, Inc.Sold out | January 04, 2021 | 0 | 0.0% |
LA JOLLA PHARMACEUTICAL COSold out | January 04, 2021 | 0 | 0.0% |
STRATA Skin Sciences, Inc. | June 23, 2020 | 1,529,392 | 4.5% |
Teligent, Inc.Sold out | February 25, 2020 | 0 | 0.0% |
Neos Therapeutics, Inc.Sold out | February 14, 2020 | 0 | 0.0% |
Aclaris Therapeutics, Inc. | February 13, 2020 | 1,888,039 | 4.6% |
Adamas Pharmaceuticals IncSold out | February 13, 2020 | 0 | 0.0% |
ADMA BIOLOGICS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
AVADEL PHARMACEUTICALS PLC | February 13, 2020 | 1,029,012 | 2.8% |
CATALYST PHARMACEUTICALS, INC.Sold out | February 13, 2020 | 0 | 0.0% |
View Broadfin Capital, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
4 | 2022-03-22 |
4 | 2022-02-15 |
4 | 2022-01-31 |
4 | 2021-11-22 |
4 | 2021-11-15 |
4 | 2021-11-09 |
4 | 2021-08-10 |
4 | 2021-05-13 |
SC 13G/A | 2021-01-04 |
SC 13G/A | 2021-01-04 |
View Broadfin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.